From the National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases: Impact of the Use of Glucose Monitoring and Control Technologies on Health Outcomes and Quality of Life in Older Adults with Type 1 Diabetes (T1D) (DP3) “Clinical and observational studies indicate that real-time information…
UF researchers are seeking to determine differences in pancreatic volume between new-onset Type 1 Diabetes (T1D) patients, antibody positive subjects at increased risk for T1D, and healthy controls. The study will also be used to determine if pancreatic volume correlates with indirect biochemical markers of endocrine and exocrine pancreatic function.
From the National Institutes of Health’s National Institute of Diabetes and Digestive and Kidney Diseases: Clinical, Behavioral and Physiological Research Testing Current and Novel Closed Loop Systems (DP3) “New technologies for monitoring blood glucose, which provide detailed information about daily glucose patterns, are already in clinical use and are…
Two recent publications explored different methods of delivering a vaccine for type 1 diabetes, both of which prevented 40 percent of mice from developing the disease.
UFDI faculty and a University of Miami researcher found that “reduced pancreas weight allows for comparisons across a wide range of donor ages by eliminating confounding variables.”…
Dr. Campbell-Thompson’s newly released publication showcases evidence that type 1 diabetes is a combined endocrine-exocrine disease in which the loss of functional beta cell mass is clinically apparent.
UFDI helped establish this new collaborative cell hub, a source for qualified scientists to access somatic and pluripotent cell lines obtained from well-phenotyped type 1 diabetes patients.
